repository
Engineering of a Cell-Penetrating Degrading Antibody to Degrade Cytosolic β-catenin by Recruiting E3 Ubiquitin Ligase
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.advisor | 김용성 | - |
| dc.contributor.author | 서지수 | - |
| dc.date.accessioned | 2022-11-29T03:01:30Z | - |
| dc.date.available | 2022-11-29T03:01:30Z | - |
| dc.date.issued | 2022-02 | - |
| dc.identifier.other | 31619 | - |
| dc.identifier.uri | https://dspace.ajou.ac.kr/handle/2018.oak/21245 | - |
| dc.description | 학위논문(석사)--아주대학교 일반대학원 :분자과학기술학과,2022. 2 | - |
| dc.description.tableofcontents | 1. Introduction 1 1.1 Cytosolic onco-protein, β-catenin 1 1.2 Cytosol-penetrating/interfering antibody 3 1.3 Targeted Protein Degradation (TPD) 4 1.4 Ubiquitin-Proteasome System (UPS) 5 2. Materials and methods 6 2.1 Cell lines 6 2.2 Construction of DNA plasmids 6 2.3 Construction of HEK293T stable cell lines 6 2.4 Generation of IgG antibodies 7 2.5 Size Exclusion Chromatography (SEC) 7 2.6 Western blot 7 2.7 Structural analysis of VHL/SOCS2 mutant fusion variants 8 2.8 Enzyme-linked immunosorbent assay (ELISA) 8 2.9 Confocal immunofluorescence microscopy 8 2.10 Flow cytometry 8 2.11 NanoLuc assay 9 2.12 Immunoprecipitation (IP) 9 2.13 Cytotoxicity assay 9 2.14 Mouse xenograft models 10 2.15 Statistical analysis 10 3. Results 11 3.1 Development of β-catenin degrading antibody 11 3.1.1 Design of β-catenin degrading antibody, Degrobody 11 3.1.2 Mechanism of action of Degrobody 12 3.2 Engineering of E3 recruiter fused antibody 14 3.2.1 Design and optimization of various inBC2-E3 recuiters 14 3.3 Engineering of VHL/SOCS2 mutant fusion variants 18 3.3.1 Design of VHL/SOCS2 mutant fusion variants 18 3.3.2 Validation of VHL/SOCS2 mutant fusion variants 21 3.4 Identification of inBC2-SOCS2-7 as a β-catenin degrader 23 3.5 inBC2-SOCS2-7 degrades cytosolic β-catenin 25 3.5.1 Characterization of inBC2-SOCS2-7 using NanoLuc assay 25 3.5.2 Cytosolic β-catenin degradation in colorectal cancer cell lines 27 3.6 Mechanism of action of inBC2-SOCS2-7 29 3.7 inBC2-SOCS2-7 degrades β-catenin using Ubiquitin-Proteasome System 31 3.8 inBC2-SOCS2-7 inhibits CRC cell growth in vitro and in vivo. 33 4. Discussion 36 CONCLUSION 37 REFERENCES 38 ABSTRACT IN KOREAN 41 | - |
| dc.language.iso | eng | - |
| dc.publisher | The Graduate School, Ajou University | - |
| dc.rights | 아주대학교 논문은 저작권에 의해 보호받습니다. | - |
| dc.title | Engineering of a Cell-Penetrating Degrading Antibody to Degrade Cytosolic β-catenin by Recruiting E3 Ubiquitin Ligase | - |
| dc.type | Thesis | - |
| dc.contributor.affiliation | 아주대학교 일반대학원 | - |
| dc.contributor.alternativeName | Ji-Su Seo | - |
| dc.contributor.department | 일반대학원 분자과학기술학과 | - |
| dc.date.awarded | 2022. 2 | - |
| dc.description.degree | Master | - |
| dc.identifier.localId | T000000031619 | - |
| dc.identifier.uci | I804:41038-000000031619 | - |
| dc.identifier.url | https://dcoll.ajou.ac.kr/dcollection/common/orgView/000000031619 | - |
| dc.subject.keyword | Colorectal cancer | - |
| dc.subject.keyword | Cullin RING E3 ligase | - |
| dc.subject.keyword | Targeted Protein Degradation | - |
| dc.subject.keyword | β-catenin | - |
| dc.description.alternativeAbstract | Abnormal activation of Wnt signaling is oncogenic and caused by mutations in the destruction complex components. β-catenin is mutated in ~80% of human Colorectal Cancers (CRC) and is one of the undruggable proteins due to its flat surfaces that lack deep binding pockets. Despite the discovery of small molecules that target the Wnt pathway, β-catenin is rarely inhibited. As same as the Targeted Protein Degradation (TPD) approach, I designed a cytosol-penetrating/degrading IgG antibody, Degrobody, which is directly bound to cytosolic β-catenin and selectively removed it, thereby suppressing its CRC cell/tumor growth. Degrobody bound to the C-terminal domain of β-catenin and recruited the CUL5 E3 ligase to induce degradation. Degrobody showed potent anti-cancer effects on a CRC xenograft model. This study offers a promising β-catenin degrading antibody that could be an effective mAb-based strategy in overcoming the limitations of existing TPD approaches. | - |
- Appears in Collections:
- Graduate School of Ajou University > Department of Molecular Science and Technology > 3. Theses(Master)
- Files in This Item:
- There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
-
- License
- STATISTICS
- Total Visit :5,252,332
- Total Download :2,137
- Today View :20,166
